×
About 51,558 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  24,401 results

Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells.
https://doi.org/10.1073/pnas.2016833118
Proceedings of the National Academy of Sciences of the Un... Owen N, Minko IG et. al.

Apr 10th, 2021 - Human clinical trials suggest that inhibition of enzymes in the DNA base excision repair (BER) pathway, such as PARP1 and APE1, can be useful in anticancer strategies when combined with certain DNA-damaging agents or tumor-specific genetic deficie...

Reinduction chemotherapy regimen involved decitabine and cladribine improves the progno...
https://doi.org/10.1002/ijc.33595
International Journal of Cancer; Hui Y, Li Y et. al.

Apr 10th, 2021 - Relapsed/refractory acute myeloid leukemia (R/R-AML) is characterized by a high incidence, short survival and poor prognosis. Presently, no unified effective reinduction chemotherapy regimen has been developed. Therefore, the use of reinduction ch...

Silencing of LINE-1 retrotransposons is a selective dependency of myeloid leukemia.
https://doi.org/10.1038/s41588-021-00829-8 10.1038/ng0598-19 10.1056/NEJMra1510092 10.1038/nrc.2017.35 10.1146/annurev-genet-110711-155616 10.1038/35057062 10.1038/s41576-019-0165-8 10.1038/332164a0 10.1146/annurev-genom-082509-141802 10.1186/s13100-016-0065-9 10.1038/s41588-019-0562-0 10.1038/s41586-019-1913-9 10.1182/blood-2013-02-474833 10.1182/blood.2019003262 10.1038/nrc3343 10.1126/science.aam7304 10.1038/nbt.3235 10.1038/nature09209 10.1038/nature25179 10.1126/science.aaa7227 10.1016/j.celrep.2016.09.050 10.1002/bies.201500184 10.1038/nrd3674 10.1126/science.1247005 10.1126/science.7660125 10.1182/blood.V96.6.2108 10.1038/nature04980 10.1186/s13100-019-0192-1 10.1016/S0092-8674(00)81998-4 10.1093/nar/28.6.1418 10.2174/1568026043388358 10.1371/journal.pone.0001547 10.1186/1471-2091-12-18 10.1016/j.ccr.2012.03.003 10.1182/blood-2016-10-696054 10.5966/sctm.2012-0109 10.1182/blood-2015-11-683649 10.1038/nm.4125 10.1038/s41467-019-09745-2 10.1038/nm.4210 10.1016/j.ccell.2017.11.012 10.1016/j.celrep.2019.07.094 10.1158/2159-8290.CD-19-0152 10.1038/s41586-018-0750-6 10.1038/nmeth.3312 10.1038/nature14136 10.1073/pnas.0605300103 10.1016/j.gene.2010.02.005 10.1038/nature13483 10.1074/jbc.M701023200 10.1083/jcb.201302092 10.1038/nm.2661 10.1016/j.ccr.2012.03.014 10.1016/j.jmb.2006.01.089 10.1186/1475-2867-6-13 10.1038/nrm2147 10.1038/s41594-020-0372-1 10.1101/gad.266098.115 10.1101/gad.343186.120 10.1038/s41586-018-0784-9 10.1016/j.cmet.2019.02.014 10.1038/ni.3558 10.1146/annurev-immunol-042718-041356 10.1182/blood-2017-06-780882 10.1038/leu.2010.324 10.1016/j.stem.2018.01.011 10.1126/science.aan4673 10.1038/nprot.2017.153 10.1093/nar/gkz365 10.1016/j.cell.2013.12.001 10.1038/s41467-020-14362-5 10.1016/j.cell.2011.03.012 10.1186/s13059-014-0554-4 10.1093/bioinformatics/btp120 10.1093/bioinformatics/btt656 10.1186/s13059-014-0550-8 10.1073/pnas.0506580102 10.1016/j.cell.2017.08.003 10.1186/gb-2009-10-3-r25 10.1186/gb-2008-9-9-r137 10.1093/nar/gkw257
Nature Genetics; Gu Z, Liu Y et. al.

Apr 9th, 2021 - Transposable elements or transposons are major players in genetic variability and genome evolution. Aberrant activation of long interspersed element-1 (LINE-1 or L1) retrotransposons is common in human cancers, yet their tumor-type-specific functi...

Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive ac...
https://doi.org/10.21037/apm-19-379
Annals of Palliative Medicine; Zhang X, Zhang X

Apr 9th, 2021 - Acute myeloid leukemia (AML) is a malignant clonal hematopoietic stem cell disease. Although there are many therapeutic options, it is still an incurable hematological malignancy. Moreover, the prognosis of AML is closely related to its cytogeneti...

see more →

Guidelines  95 results

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 23rd, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML
https://ascopost.com/news/june-2020/ivosidenib-plus-venetoclax-with-or-without-azacitidine-for-idh1-mutated-aml/

May 31st, 2020 - Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML...

AMG 330 Shows Promise in Treating Relapsed/Refractory AML
https://www.onclive.com/conference-coverage/asco-2020/amg-330-shows-promise-in-treating-relapsedrefractory-aml

May 29th, 2020 - Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia (AML), with cytokine release syndrome (CRS) as the most frequent and expected adverse event (AE), according to preliminary ...

Palliative Care Improves Quality of Life in Patients With AML
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/

May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter...

High Expression of DOCK2 Indicates Good Prognosis in AML
https://www.jcancer.org/v10p6088.htm
Journal of Cancer; Hu N,et al

Oct 14th, 2019 - DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML).

see more →

Drugs  59 results see all →

Clinicaltrials.gov  25,501 results

Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells.
https://doi.org/10.1073/pnas.2016833118
Proceedings of the National Academy of Sciences of the Un... Owen N, Minko IG et. al.

Apr 10th, 2021 - Human clinical trials suggest that inhibition of enzymes in the DNA base excision repair (BER) pathway, such as PARP1 and APE1, can be useful in anticancer strategies when combined with certain DNA-damaging agents or tumor-specific genetic deficie...

Reinduction chemotherapy regimen involved decitabine and cladribine improves the progno...
https://doi.org/10.1002/ijc.33595
International Journal of Cancer; Hui Y, Li Y et. al.

Apr 10th, 2021 - Relapsed/refractory acute myeloid leukemia (R/R-AML) is characterized by a high incidence, short survival and poor prognosis. Presently, no unified effective reinduction chemotherapy regimen has been developed. Therefore, the use of reinduction ch...

Silencing of LINE-1 retrotransposons is a selective dependency of myeloid leukemia.
https://doi.org/10.1038/s41588-021-00829-8 10.1038/ng0598-19 10.1056/NEJMra1510092 10.1038/nrc.2017.35 10.1146/annurev-genet-110711-155616 10.1038/35057062 10.1038/s41576-019-0165-8 10.1038/332164a0 10.1146/annurev-genom-082509-141802 10.1186/s13100-016-0065-9 10.1038/s41588-019-0562-0 10.1038/s41586-019-1913-9 10.1182/blood-2013-02-474833 10.1182/blood.2019003262 10.1038/nrc3343 10.1126/science.aam7304 10.1038/nbt.3235 10.1038/nature09209 10.1038/nature25179 10.1126/science.aaa7227 10.1016/j.celrep.2016.09.050 10.1002/bies.201500184 10.1038/nrd3674 10.1126/science.1247005 10.1126/science.7660125 10.1182/blood.V96.6.2108 10.1038/nature04980 10.1186/s13100-019-0192-1 10.1016/S0092-8674(00)81998-4 10.1093/nar/28.6.1418 10.2174/1568026043388358 10.1371/journal.pone.0001547 10.1186/1471-2091-12-18 10.1016/j.ccr.2012.03.003 10.1182/blood-2016-10-696054 10.5966/sctm.2012-0109 10.1182/blood-2015-11-683649 10.1038/nm.4125 10.1038/s41467-019-09745-2 10.1038/nm.4210 10.1016/j.ccell.2017.11.012 10.1016/j.celrep.2019.07.094 10.1158/2159-8290.CD-19-0152 10.1038/s41586-018-0750-6 10.1038/nmeth.3312 10.1038/nature14136 10.1073/pnas.0605300103 10.1016/j.gene.2010.02.005 10.1038/nature13483 10.1074/jbc.M701023200 10.1083/jcb.201302092 10.1038/nm.2661 10.1016/j.ccr.2012.03.014 10.1016/j.jmb.2006.01.089 10.1186/1475-2867-6-13 10.1038/nrm2147 10.1038/s41594-020-0372-1 10.1101/gad.266098.115 10.1101/gad.343186.120 10.1038/s41586-018-0784-9 10.1016/j.cmet.2019.02.014 10.1038/ni.3558 10.1146/annurev-immunol-042718-041356 10.1182/blood-2017-06-780882 10.1038/leu.2010.324 10.1016/j.stem.2018.01.011 10.1126/science.aan4673 10.1038/nprot.2017.153 10.1093/nar/gkz365 10.1016/j.cell.2013.12.001 10.1038/s41467-020-14362-5 10.1016/j.cell.2011.03.012 10.1186/s13059-014-0554-4 10.1093/bioinformatics/btp120 10.1093/bioinformatics/btt656 10.1186/s13059-014-0550-8 10.1073/pnas.0506580102 10.1016/j.cell.2017.08.003 10.1186/gb-2009-10-3-r25 10.1186/gb-2008-9-9-r137 10.1093/nar/gkw257
Nature Genetics; Gu Z, Liu Y et. al.

Apr 9th, 2021 - Transposable elements or transposons are major players in genetic variability and genome evolution. Aberrant activation of long interspersed element-1 (LINE-1 or L1) retrotransposons is common in human cancers, yet their tumor-type-specific functi...

Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive ac...
https://doi.org/10.21037/apm-19-379
Annals of Palliative Medicine; Zhang X, Zhang X

Apr 9th, 2021 - Acute myeloid leukemia (AML) is a malignant clonal hematopoietic stem cell disease. Although there are many therapeutic options, it is still an incurable hematological malignancy. Moreover, the prognosis of AML is closely related to its cytogeneti...

see more →

News  1,495 results

Whole-Genome Sequencing Emerging for Routine Cancer Care
https://www.medscape.com/viewarticle/947261

Mar 10th, 2021 - Almost 20 years after the human genome was first mapped, whole-genome sequencing might finally be ready to enter routine cancer care. Researchers at Washington University in St. Louis, St. Louis, Missouri, are commercializing an automated sequenci...

FDA Places Clinical Hold on Sickle Cell Gene Therapy
https://www.medscape.com/viewarticle/946434

Feb 23rd, 2021 - Updated February 25, 2021 // Editor’s note: The original text has been corrected to accurately reflect the status of the patients with AML and MDS. The FDA placed a clinical hold yesterday on two gene therapy trials for sickle cell disease (SCD) a...

Fast Five Quiz: Myelodysplastic Syndrome
https://reference.medscape.com/viewarticle/943967

Jan 27th, 2021 - Myelodysplastic syndrome (MDS) is a group of related hematopoietic disorders characterized by peripheral blood cytopenias, abnormal blood cell development, and clonal genetic markers. Patients with MDS may present with clinical manifestations of a...

Leukemia: New Adverse Event With PARP Inhibitors in Cancer
https://www.medscape.com/viewarticle/943743

Jan 6th, 2021 - A new adverse event has been reported for PARP inhibitor drugs used in the treatment of cancer: the risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), both of which have a high mortality rate.   PARP inhibitors are...

Black Race Linked to Poorer Survival in AML
https://www.medscape.com/viewarticle/942309

Dec 8th, 2020 - Black race is the most important risk factor for patients with acute myeloid leukemia (AML) and is associated with poor survival, according to new findings. Among patients with AML younger than 60 years, the rate of overall 3-year survival was sig...

see more →

Patient Education  7 results see all →